Nebenwirkungen · Yescarta
Yescarta 0.4 – 2 × 108 cells dispersion for infusion · Abschnitt 4.8 · PDF-Seite 11
HOS-139697 · Präparat HOS-098384
System Organ Class (SOC) Frequency Adverse reactions Infections and infestations Very common Unspecified pathogen infections Viral infection Bacterial infection Common Fungal infection Neoplasms benign, malignant and unspecified (including cysts and polyps) Uncommon Secondary malignancy of T-cell origin Blood and lymphatic system disorders Very common Febrile neutropenia# Neutropenia# Lymphopenia# Leukopenia# Anaemia# Thrombocytopenia# Common Coagulopathya Immune system disorders Very common Cytokine Release Syndrome Immunoglobulins decreasedb Common Hypersensitivity Uncommon Haemophagocytic lymphohistiocytosis* Metabolism and nutrition disorders Very common Hyponatraemia# Hypophosphataemia# Hyperuricemia#** Hyperglycaemia# Decreased appetitec Common Hypokalaemia# Hypocalcaemia# Hypoalbuminaemia# Dehydrationd Weight decreased Psychiatric disorders Very common Deliriume Insomnia Common Anxiety Affective disorderf
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-08T14:29:00Z · SHA-256 7364b8713752a41eb6e8333150b68c1c6ab4a679e9b42caeedeacec6f055396e · Passage d37be712a49b68bab556e5b512fb7b8d2b5848ef52e60e8f55752cc4f8811b83 · Zeichen 4639–7693 im Abschnitt